Inhaled nitric oxide (NO) is a medical treatment that involves the use of a gas that lies between three medical specialties: cardiology, pulmonology, and critical care. Doctors use it to control pulmonary vascular tone, improve ventilation–perfusion matching, and support the right ventricle during periods of increased afterload. Nevertheless, the therapy’s effectiveness has depended on large, heavy cylinders, complex delivery hardware, and the need for specially trained personnel. This equipment determines which patients can receive NO, when it can be started, and the duration of therapy. Thus, device and drug developers have been continuously attracted to the idea of making delivery more compact, simple, and less risky.
One of the body’s natural sources of NO is endothelial nitric oxide synthase. It goes into smooth muscle and activates guanylate cyclase through calcium, which lowers. The outcome is that NO inhalation leads to selective pulmonary vasodilation in those lung units that received the gas. Generally, systemic blood pressure is maintained because NO is rapidly bound by hemoglobin. In acute care facilities, these features of the therapy can lead to a drop in pulmonary vascular resistance, relief of right ventricular afterload, and improved forward flow, most notably in right-sided failure after left-ventricular assist device (LVAD) implantation, cardiopulmonary bypass, or decompensated pulmonary hypertension.
Conventional delivery depends on bulk tanks or high-pressure cylinders, gas monitors, and scavenging systems. Transport inside hospitals can be cumbersome. Community sites often defer use due to storage limits, staff training requirements, and logistics-related cost structures. Compact on-demand generation, if accurate in dose, stable over time, and safe from nitrogen dioxide (NO₂) by-products, offers a route to expand access while lowering the footprint around the bedside and during transport.
GeNO LLC, led for years by biomedical scientist Kurt A. Dasse, Ph.D., framed inhaled NO as a combination product: a delivery device tightly coupled to the “drug” being generated at the point of care. The strategy ties engineering controls (sensors, flow paths, algorithms) to clinical dose specifications, so the therapeutic and the mechanism that produces it move through development together. That framing also sets expectations for manufacturing, quality, and human-factors testing from the outset.
Any system that provides gas on demand has to change a precursor to NO, and at the same time, it must not allow the accumulation of NO₂, which irritates the lungs. GeNO’s solution focuses on controlled surface chemistry and scavenging media that remove or neutralize NO₂ before delivery to the patient. The engineering problem is a moving one: generation has to follow the setpoint as flow changes with ventilation and patient demand, while downstream scrubbing keeps oxidative by-products from reaching the circuit. Stability in variable humidity, temperature, and flow is a design requirement, not an exception.
Closed-loop control, redundant sensing, and alarm hierarchies are the platform’s foundation. Continuous measurement at or near the patient interface confirms the set dose, while upstream checks monitor precursors, filters, and NO₂ levels. Alarm logic identifies the most important faults (e.g., overdose risk, NO₂ spike) as those that require immediate action and interruption of therapy, while other conditions (e.g., cartridge nearing end of life) can be addressed without therapy interruption. Event logs and dose histories are there to facilitate clinical documentation and post-market surveillance.
Combination products draw input from the FDA’s device and drug centers (CDRH and CDER). For inhaled NO, device accuracy and reliability must align with clinical pharmacology and labeling. Under Dasse’s leadership, GeNO structured submissions to address both sides: bench and simulated-use testing to validate delivery accuracy; chemistry, manufacturing, and controls for precursors and scavengers; and risk files that link hazards to mitigations traceable through design controls.
Traditional NO use skews acute and inpatient. GeNO’s roadmap included chronic or extended use scenarios where home initiation or hospital-to-home transitions may be considered. Human-factors studies, therefore, expand beyond respiratory therapists to include nurses, patients, and caregivers, with tasks such as cartridge changes, verification routines, and transport workflows validated against foreseeable use errors. Labeling, training, and UI design are integrated deliverables, not optional add-ons.
In pulmonary arterial hypertension (PAH) and secondary forms of elevated pulmonary pressure, inhaled NO can test vasoreactivity and, in selected settings, provide temporizing support. In surgical programs, postoperative RHF remains a material source of morbidity after LVAD implantation. Teams deploy inhaled NO to reduce pulmonary vascular load and support right-sided output during the vulnerable early period. A compact system that moves with the patient, from OR to ICU to step-down, seeks to maintain continuity without cylinder swaps or setup delays.
GeNO’s clinical development has emphasized collaboration with centers that track standardized endpoints: changes in mean pulmonary artery pressure, cardiac index, mixed venous oxygen saturation, weaning success, ventilator-free days, ICU length of stay, and safety measures such as methemoglobin and NO₂ exposure. For LVAD cohorts, endpoints add right-ventricular assist device (RVAD) avoidance and diuretic/inotrope requirements. The trials aim to demonstrate not only physiological response but also operational reliability in high-acuity settings.
The commercial thesis links portability to the predictable cost of care. Cartridge-based generation and small consoles reduce storage, rental, and transport overhead. Training modules target rapid competency, device checks, cartridge management, alarm response, and integration with ventilators or high-flow nasal cannula systems. For administrators, a compact platform can simplify procurement and broaden availability beyond tertiary ICUs.
The competitive set includes incumbent cylinder-based NO systems, aerosolized pulmonary vasodilators (e.g., prostacyclin analogs), and oral or parenteral agents used chronically in PAH. Cylinder incumbents benefit from installed base and familiarity; nebulized agents avoid gas infrastructure altogether but rely on different pharmacology and deposition patterns. In this landscape, on-demand NO competes on accuracy, simplicity, NO₂ control, and total cost of ownership, not on claims of clinical superiority across all indications.
If subsequent use is intended for chronic or intermittent situations at home, more emphasis will have to be placed on human-factors validation, cybersecurity, and remote monitoring. Through connectivity, clinical teams can receive dose logs, alarm histories, and adherence data. Moreover, integrating electronic health records and pulmonary hypertension registries may facilitate longitudinal outcomes research while preserving privacy. Alongside this, supply-chain planning should provide not only a reliable supply of cartridges but also a clear way to handle end-of-life.
Kurt A. Dasse, Ph.D. is a physiologist and medical-device executive whose career has been like a trail that follows the shift of complex cardiopulmonary technologies from large, fixed systems to smaller, more controllable platforms. In his initial roles within the HeartMate LVAD program, he was made aware of the right-heart complications after the left-sided support and the operational realities that influence the adoption. After that, he was the co-founder and leader of Levitronix’s medical business, which created magnetically levitated centrifugal pumps for use in adult and pediatric circulatory support. The programs were highly demanding in terms of design controls, crisis management, and multi-center clinical coordination, skills directly applicable to combination-product development.
At GeNO, Dasse applied that operating model to inhaled NO: define the therapy as a tightly integrated device–drug system; design for accuracy and safety under variable clinical conditions; and structure regulatory and human-factors work to support both inpatient and potential extended-use pathways. The platform reflects a consistent philosophy: pair physiologic specificity (selective pulmonary vasodilation without systemic hypotension) with delivery systems that reduce logistical friction. In this framing, innovation is not only about generating a molecule; it is about the reliability of generation, measurement, and documentation at the point of care.
The clinical rationale remains practical. Programs that implant LVADs or manage advanced pulmonary hypertension already rely on inhaled NO in defined scenarios. If a compact, accurate generator can lower barriers to initiation and continuation while maintaining NO₂ control and dose fidelity, the addressable use cases expand: intra-hospital transport, step-down units, and, with appropriate evidence, outpatient transitions. Each step requires evidence, not assumptions, bench validation of dose accuracy, controlled assessments of NO₂ scavenging efficacy, and trials with endpoints that matter to clinicians and administrators.
Market dynamics will continue to shape adoption. Cylinder-based incumbents offer predictability and a service model built over decades. Nebulized alternatives offer pharmacologic options without the need for gas logistics. A combination-product entrant must compete on quantifiable attributes, dose precision, alarm performance, training time, portability, and cost per treated hour, while meeting the documentation demands of hospitals and payers. The discipline Dasse brings from prior device programs centers on those measurable factors.
Looking forward, the most consequential questions are less about generating NO and more about the ecosystem around it. Can dose and safety data flow securely to care teams without adding burden? Can training frameworks support consistent use across staffing models and hospital sizes? Can supply chains deliver cartridges with the same predictability that cylinders once did? The answers will determine whether on-demand inhaled NO remains a specialized alternative or becomes a routine option across diverse care settings.
For now, the case for compact NO rests on familiar clinical physiology, coupled with engineering that aims to make a selective pulmonary vasodilator simpler to deploy, track, and sustain. In that sense, the GeNO effort under Dasse’s leadership fits a broader pattern in cardiopulmonary care: refine the therapy, then redesign the delivery so that more patients can receive it where and when it is needed.
Disclaimer: The content of this article is intended for informational purposes only and does not constitute medical advice. The statements regarding the use of inhaled nitric oxide (NO) and its associated therapies are based on current clinical research and are subject to regulatory review. Always consult a healthcare provider for personalized medical advice and treatment options.
